[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] KHEMLMA G, IKEDA S, KURZROCK R.The biology of Hepatocellular carcinoma: implications for genomic and immune therapies[J]. Mol Cancer, 2017, 16(1):149.
[3] RAHBARI NN, MEHRABI A, MOLLBERG NM, et al.Hepatocellular carcinoma: current management and perspectives for the future[J]. Ann Surg, 2011, 253(3):453-69.
[4] 王波, 钱叶本, 罗雪莲, 等. 肝癌复发的诊断与治疗进展[J]. 肝胆外科杂志, 2016, 24(4):307-312.
[5] 严文韬, 邢昊, 王明达, 等. 肝癌术后复发的治疗选择[J/CD].中华肝脏外科手术学电子杂志, 2019, 8(5):396-399.
[6] 原发性肝癌诊疗规范(2017年版)[J/CD].消化肿瘤杂志(电子版), 2017, 9(4):213-228.
[7] 熊超杰, 胡杨科, 虞哲伟, 等. 术后经导管(肝)动脉栓塞化疗对合并微血管侵犯的肝癌患者预后影响的研究进展[J].中华肝胆外科杂志, 2019, 25(8):631-633.
[8] WANG Z, REN Z, CHEN Y, et al.Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study[J]. Clin Cancer Res, 2018, 24(9):2074-2081.
[9] WILHELM SM, DUMAS J, ADNANE L, et al.Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer, 2011, 129(1):245-255.
[10] BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66. |
